For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Is This 1 Momentum Stock a Screaming Buy Right Now?

Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

Amedisys (AMED)

Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, as well as various rehabilitative programs. It provides hospice services to patients through an interdisciplinary care team which includes nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains. Amedisys was founded in 1982 and is headquartered in Baton Rouge, LA.

AMED is a Zacks Rank #2 (Buy) stock, with a Momentum Style Score of B and VGM Score of B. Shares are up 0.9% over the past one week and up 6.8% over the past four weeks. AMED has gained 7.8% in the last one-year period as well. Looking at trading volume, an average of 431,356.81 shares exchanged hands over the last 20 trading days.

Momentum investors also pay close attention to a company's earnings. For AMED, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0 to $4.57 per share for 2024. AMED boasts an average earnings surprise of 2.8%.

With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding AMED to their portfolios.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amedisys, Inc. (AMED):Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research